文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

仅观察的儿童难治性血细胞减少症患者的长期结局

Long-term outcomes of patients with refractory cytopenia of childhood under observation only.
PubMed 文献 · Blood Adv · 2025-01-01

本研究评估了100例无遗传易感证据、核型正常且诊断后2年内未接受造血干细胞移植或免疫抑制治疗的儿童难治性血细胞减少症(RCC)患者的长期结局,中位随访7.2年,5年和10年无造血干细胞移植生存率分别为94%和88%,所有患者末次随访时均存活。

要点

  • 儿童难治性血细胞减少症(RCC)以持续血细胞减少、发育异常及独特骨髓病理为特征。
  • 核型正常且排除胚系易感综合征的RCC患者,观察策略在所选患者中是安全的。
  • 多数患者血细胞减少持续存在,强调长期监测及向成人血液科过渡的重要性。

核心结论

  • 对于核型正常且排除胚系易感综合征的所选儿童难治性血细胞减少症(RCC)患者,观察策略是安全的。
  • 多数患者血细胞减少持续存在,强调长期监测及向成人血液科过渡的重要性。

研究设计与样本

  • 评估100例无遗传易感证据、核型正常且诊断后2年内未接受造血干细胞移植(HSCT)或免疫抑制治疗的儿童难治性血细胞减少症(RCC)患者的长期结局。
  • 患者诊断时中位年龄为10.9岁(范围1.4-17.3岁),84%表现为骨髓低增生。
  • 试验注册号为NCT00047268和NCT00662090。

主要发现

  • 3例(3%)出现核型异常的克隆演变,1例进展为伴原始细胞增多的骨髓增生异常综合征。
  • 3例(3%)发生阵发性睡眠性血红蛋白尿。
  • 9例(9%)接受造血干细胞移植(HSCT),5年和10年无HSCT生存率分别为94%和88%。
  • 末次随访时所有患者均存活,中位随访时间为7.2年。

临床怎么用

  • 对于核型正常且排除胚系易感综合征的所选儿童难治性血细胞减少症(RCC)患者,可考虑观察策略。
  • 作者强调长期监测及向成人血液科过渡的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Refractory cytopenia of childhood (RCC) describes an entity of well-recognized bone marrow failure defined by persistent cytopenia, dysplastic changes, and a unique histopathological pattern in the bone marrow. Although hematopoietic stem cell transplantation (HSCT) is generally indicated for patients with severe cytopenia or abnormal karyotype, a subset of patients with RCC may be candidates for an observational approach. We evaluated the long-term outcome of patients with RCC without evidence of a genetic predisposition who had a normal karyotype and had not received HSCT or immunosuppressive therapy within 2 years from diagnosis. The median age at diagnosis of the 100 patients analyzed was 10.9 years (range 1.4-17.3); 84% presented with a hypocellular bone marrow. Clonal evolution with abnormal karyotype occurred in 3 patients (3%), and 1 case progressed to myelodysplastic syndrome with excess blasts. Three patients (3%) developed paroxysmal nocturnal hematuria. Overall, 9 patients (9%) received HSCT, and the 5- and 10-year HSCT-free survival was 94% and 88%, respectively. At last follow-up, all patients were alive with a median follow-up time of 7.2 years. These results indicate that an observational approach is safe for selected patients with RCC with a normal karyotype after an exclusion of a germ line predisposition syndrome. However, persistence of cytopenia in most of these patients underscores the importance of long-term surveillance and transition to adult hematology care. This trial was registered at www.clinicaltrials.gov as #NCT00047268 and #NCT00662090.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Drexler B, Schwarz-Furlan S, Baumann I, et al. Long-term outcomes of patients with refractory cytopenia of childhood under observation only. Blood Adv. 2025. PMID: 40554414. doi:10.1182/bloodadvances.2025016136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。